宜明昂科-B(01541.HK)发布公告称,公司与Instil已自美国食品药品监督管理局取得IMM2510/AXN-2510的新药临床试验(IND)批准,预计将在2025年底前启动,IMM2510/AXN-2510作为用于治疗复发性/难治性实体肿瘤患者的1b/2期试验,可评估在实体肿瘤患者中的安全性、疗效、药物代谢动力学及药效学。
宜明昂科-B(01541.HK)发布公告称,公司与Instil已自美国食品药品监督管理局取得IMM2510/AXN-2510的新药临床试验(IND)批准,预计将在2025年底前启动,IMM2510/AXN-2510作为用于治疗复发性/难治性实体肿瘤患者的1b/2期试验,可评估在实体肿瘤患者中的安全性、疗效、药物代谢动力学及药效学。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.